NPPB and cardiovascular disorder: In summary, these findings suggest that a simple test of biomarkers (i.e., proBNP and ALB) may stratify the risk of prognosis in patients with CAD and provide treatment strategies aimed at reducing future cardiovascular disease morbidity and mortality.